Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2002

View Archived Issues

Efficacy of HCT-1026 as a treatment for overactive bladder in women

NS-8 reverses bladder hyperactivity in rats without affecting blood pressure or heart rate

Rho/Rho kinase pathway involved in spontaneous myogenic tone of isolated pig urethra

Enrollment completed in Repel-CV trial

Xention Discovery created following CeNeS technology acquisition

Kirin initiates phase II Mylovenge trials in Japan

TLK-286 to enter phase III by first quarter 2003

Ark and Tanabe collaborate on cachexia product development

Lexapro launched for major depressive disorder

Eligard 22.5 mg launched

Rosuvastatin: superior cholesterol control compared to atorvastatin and potential in stroke

IL-10 gene transfer suppresses autoimmune myocarditis in Lewis rats

Data presented at ESC 2002 support further clinical evaluation of AR-C69931MX in myocardial ischemia

ATL-962 significantly increases fat excretion in phase Ib studies

Improved oral bioavailability achieved in dihydropyridine Y1 receptor antagonists

Potent and orally active Lck inhibitors with activity in animal models of T-cell activation

Phase III Cidecin trial in endocarditis and bacteremia enrolls first patients

Symlin dose-titration study fully enrolled

Bay-43-9006 enters phase II

Arimidex approved in early breast cancer

Sumitomo presents novel agents for arthritis and bone disorders

New bronchodilators prepared and tested at Mercian

Novel inhibitors of VEGF expression covered by Mercian patent

New adenosine A2A antagonists and their use in Parkinson's disease described by Vernalis

Novel NOS inhibitors in early development at Fujisawa

Novel COX-1 inhibitors with analgesic activity described by Fujisawa

Novel antitumor compounds isolated from Clavularia corals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...